EvolveImmune Therapeutics
Pre-clinicalA biotechnology company developing novel cancer immunotherapies using its proprietary EVOLVE platform to create targeted T-cell engagers.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $52M
About
A biotechnology company developing novel cancer immunotherapies using its proprietary EVOLVE platform to create targeted T-cell engagers.
Biologics
Funding History
2Total raised:$52M
Series A$40MMar 15, 2023
Seed$12MSep 15, 2021